Dosing & Uses
Dosage Forms & Strengths
20-40 mg PO at onset of symptoms; repeat dose after 2 hr if necessary
Not to exceed 80 mg/day
Monitor for increase in blood pressure; dose adjustment not necessary
Mild to moderate impairment: Dose adjustment not necessary
Severe impairment: Do not administer
<18 years old: Not recommended
Migraine headache: See adult dosing
Serious - Use Alternative
Significant - Monitor Closely
Chest pain/tightness (1-4%)
Abdominal pain/discomfort (>1%)
Back pain (>1%)
Hypersensitivity, including angioedema and anaphylaxis
History of CAD or coronary artery vasospasm
Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
History of stroke or TIA, or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke
Peripheral vascular disease
Ischemic bowel disease
Severe hepatic impairment
Do not use within 24 hr of another 5-HT1 agonist or ergot derivative
Within at least 72 hr of treatment with the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir
Overuse of acute migraine drugs (eg, ergotamine, triptans, opioids, or combination of these drugs for ≥10 days/month) may lead to exacerbation of headache (medication overuse headache)
Myocardial ischemia/infarction or Prinzmetal’s angina reported (see Contraindications)
Life-threatening cardiac rhythm disturbances including VT and VFIB leading to reported within a few hr following the administration of 5-HT1 agonists
Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5-HT1 agonists, and some have resulted in fatalities
Sensations of tightness, pain, and pressure in the chest, throat, neck, and jaw commonly occur after treatment and are usually non-cardiac in origin; however, perform a cardiac evaluation in patients at high cardiac risk
Significant increase in blood pressure including hypertensive crisis with acute impairment of organ systems reported
Anaphylaxis/anaphylactoid and hypersensitivity reactions, including angioedema reported (see Contraindications)
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Enters breast milk; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Selective 5-HT1 receptor agonist in cranial arteries. Causes vasoconstriction and reduces inflammation associated with antidronic neuronal transmission associated with relief of migraine
Half-Life elimination: 4 hr
Peak Plasma Time: 1.5-2 hr
Protein bound: 85%
Vd: 138 L
Metabolism: hepatic CYP3A4
Metabolites: N-demethylated eletriptan (10-20%)
Renal Clearance: 3.9 L/hr
Excretion: 90% Non-renal
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs